

Mustang Bio closes \$20 million venture debt financing with Horizon Technology Finance Corporation

Torreya served as financial advisor to Mustang Bio, Inc.

New York, NY, and Farmington, CT, April 1, 2019

Mustang Bio Inc. (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on cell and gene therapies, announced today that it has entered into a \$20 million venture debt financing agreement with Horizon Technology Finance Corporation (NASDAQ: HRZN), a specialty finance company focused on securing loans to venture capital backed companies. The financing provides Mustang with additional working capital to develop their gene and cell therapies in their cell processing facility.

Fifteen million was funded upon closing, the remaining \$5 million will be funded upon Mustang achieving certain predetermined milestones. Each advance of the loan will be repaid in 42 monthly payments consisting of 18 monthly payments of interest only, followed by 24 monthly payments of principal and accrued interest, and will be payable monthly in arrears. The interest-only period may be extended to 24 months contingent upon Mustang achieving certain milestones. In connection with the debt financing, Mustang issued Horizon warrants to purchase up to 288,184 of its common shares at an exercise price of \$3.47 per share.

Torreya served as financial advisor to Mustang in the financing. Our Capital Markets team continues to be dedicated to raising capital for our corporate clients via equity, debt and royalty monetizations. Our capital markets team has raised \$400 million in capital for our clients since the beginning of 2018. This transaction also reinforces Torreya's strength and leadership position as an advisor to biotechnology companies.

ABOUT MUSTANG BIO, INC.

For more information about Mustang, please see: www.mustangbio.com

ABOUT HORIZON TECHNOLOGY FINANCE MANAGEMENT LLC

For more information about Horizon Technology Finance, please see: www.horizontechfinance.com

Deal Press Release

Torreya Contact

TOM BABICH

Head of Capital Markets | New York Office

tom.babich@torreya.com | 212.257.5811 | torreya.com



Torreya is a global advisory firm serving the life sciences industry. Please visit torreya.com for more information. Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. Torreya Partners LLC is a Delaware Limited Liability Company while Torreya Partners (Europe) LLP is a limited liability partnership, registered in England and Wales, registered number OC362930. Registered office: 150 Aldersgate Street, London EC1A 4AB. Torreya Partners (Europe) LLP is authorized and regulated by the Financial Conduct Authority. The information contained in the email and/or its attachments is confidential and/or privileged and is for the sole use of the intended recipient(s). If you are not the intended recipient, please notify the sender immediately by reply and immediately delete this message and all its attachments. Any review, use, reproduction, disclosure or dissemination of the message or any attachment by an unintended recipient is strictly prohibited. Neither this message nor any attachment is intended as or should be construed as an offer, solicitation or recommendation to buy or sell any security or other financial instrument. This communication is for informational purposes only. All investments involve risks including loss of principal invested. Past performance does not guarantee future results or success. Torreya Capital and its representatives do not provide tax or legal advice and each tax and financial situation is unique. Investors should consult their tax and/or legal advisor for advice and information concerning their particular situation.